TY - JOUR
T1 - The Delivery of Small Interfering RNA to Hepatic Stellate Cells Using a Lipid Nanoparticle Composed of a Vitamin A-Scaffold Lipid-Like Material
AU - Toriyabe, Naoyuki
AU - Sakurai, Yu
AU - Kato, Akari
AU - Yamamoto, Shoshiro
AU - Tange, Kota
AU - Nakai, Yuta
AU - Akita, Hidetaka
AU - Harahsima, Hideyoshi
N1 - Funding Information:
The authors wish to thank to Dr. Milton S. Feather for modifying the manuscript. This study was supported partly by research grants (Research on Development of New Drugs, Health and Labour Sciences Research Grant, and Initiative for Accelerating Regulatory Science in Innovative Drug, Medical Device, and Regenerative Medicine) from the Japan Ministry of Health (H24B-14), Labour and Welfare, Research Program on Hepatitis from Japanese Agency for Medical Research and Development and Grant-in-Aid for Japan Society for the Promotion of Science Fellows (13J05890).
Publisher Copyright:
© 2017 American Pharmacists Association®
PY - 2017/8
Y1 - 2017/8
N2 - Hepatic stellate cells (HSCs) are responsible for hepatic fibrosis and liver cirrhosis via their ability to produce extracellular matrices such as collagens and elastin. However, a strategy for delivering cargoes to HSCs has not been established yet. We herein report on attempts to deliver small interfering RNA (siRNA) to HSCs using several types of SS-cleavable proton-activated lipid-like materials (ssPalms) that contained myristic acid (ssPalmM) or hydrophobic vitamin A (ssPalmA) and E (ssPalmE) as hydrophobic scaffolds. We initially verified that hepatic fibrosis could induce the treatment with tetrachloromethane in terms of collagen fibrils and the expression of marker genes, type I collagen α-1, transforming growth factor β, heat shock protein 47, and α-smooth muscle actin. The siRNA silencing efficiency of the 3 LNPs was then compared using fibrosis-induced mice. Of the materials tested, LNPssPalmA showed the highest efficiency, with an effective (ED)50 of approximately 0.25 mg siRNA/kg. The LNPssPalmA showed a significant inhibitory effect on collagen production at a dose of 3.0 mg siRNA/kg with no evidence of any severe adverse effects. In conclusion, LNPssPalmA holds considerable potential for use in the treatment of HSCs-mediated diseases.
AB - Hepatic stellate cells (HSCs) are responsible for hepatic fibrosis and liver cirrhosis via their ability to produce extracellular matrices such as collagens and elastin. However, a strategy for delivering cargoes to HSCs has not been established yet. We herein report on attempts to deliver small interfering RNA (siRNA) to HSCs using several types of SS-cleavable proton-activated lipid-like materials (ssPalms) that contained myristic acid (ssPalmM) or hydrophobic vitamin A (ssPalmA) and E (ssPalmE) as hydrophobic scaffolds. We initially verified that hepatic fibrosis could induce the treatment with tetrachloromethane in terms of collagen fibrils and the expression of marker genes, type I collagen α-1, transforming growth factor β, heat shock protein 47, and α-smooth muscle actin. The siRNA silencing efficiency of the 3 LNPs was then compared using fibrosis-induced mice. Of the materials tested, LNPssPalmA showed the highest efficiency, with an effective (ED)50 of approximately 0.25 mg siRNA/kg. The LNPssPalmA showed a significant inhibitory effect on collagen production at a dose of 3.0 mg siRNA/kg with no evidence of any severe adverse effects. In conclusion, LNPssPalmA holds considerable potential for use in the treatment of HSCs-mediated diseases.
KW - drug delivery systems
KW - hepatocytes
KW - liposomes
KW - siRNA
KW - site-specific delivery
UR - http://www.scopus.com/inward/record.url?scp=85020010641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020010641&partnerID=8YFLogxK
U2 - 10.1016/j.xphs.2017.04.042
DO - 10.1016/j.xphs.2017.04.042
M3 - Article
C2 - 28456722
AN - SCOPUS:85020010641
SN - 0022-3549
VL - 106
SP - 2046
EP - 2052
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 8
ER -